KalVista Pharmaceuticals, Inc. Common Stock (KALV)

Price$26.94

Value ScoreD

Growth ScoreB

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)90.44%

Price vs S&P 500 (4W)-4.15%

VGM Score61.12

Market Capitalization$1.43B

All Metrics

Book Value / Share (Quarterly)$0.34

P/TBV (Annual)1.74x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.92

Price vs S&P 500 (YTD)55.44%

Gross Margin (TTM)92.60%

Net Profit Margin (TTM)-91.58%

EPS (TTM)$-1.58

10-Day Avg Trading Volume4.05M

EPS Excl Extra (TTM)$-1.58

Revenue Growth (5Y)31.06%

EPS (Annual)$-2.03

ROI (Annual)-61.30%

Gross Margin (Annual)93.72%

Net Profit Margin (5Y Avg)-402.03%

Cash / Share (Quarterly)$5.56

ROA (Last FY)-32.66%

EBITD / Share (TTM)$-1.56

ROE (5Y Avg)-43.24%

Operating Margin (TTM)-93.90%

Cash Flow / Share (Annual)$-1.64

P/B Ratio84.16x

P/B Ratio (Quarterly)36.20x

Net Income / Employee (Annual)$-398,300

EV / Revenue (TTM)16.30x

Net Interest Coverage (TTM)-43.96x

ROA (TTM)-27.44%

EPS Incl Extra (Annual)$-2.03

Current Ratio (Annual)5.58x

Quick Ratio (Quarterly)4.97x

3-Month Avg Trading Volume2.51M

52-Week Price Return125.99%

Revenue / Employee (TTM)$332,200

Tangible BV / Share (Quarterly)$4.07

P/S Ratio (Annual)29.15x

Asset Turnover (Annual)0.15x

52-Week High$26.87

Operating Margin (5Y Avg)-488.97%

EPS Excl Extra (Annual)$-2.03

CapEx CAGR (5Y)88.34%

Tangible BV CAGR (5Y)42.66%

26-Week Price Return106.37%

Quick Ratio (Annual)5.43x

13-Week Price Return70.49%

Total Debt / Equity (Annual)1.11x

Current Ratio (Quarterly)5.17x

Enterprise Value$1.49B

Revenue / Share Growth (5Y)4.97%

Asset Turnover (TTM)0.30x

Book Value / Share Growth (5Y)-16.43%

Revenue / Employee (Annual)$178,500

Pretax Margin (Annual)-225.27%

Cash / Share (Annual)$5.90

3-Month Return Std Dev91.84%

Net Income / Employee (TTM)$-304,300

ROE (Last FY)-61.30%

Net Interest Coverage (Annual)-1.82x

EPS Basic Excl Extra (Annual)$-2.03

Total Debt / Equity (Quarterly)16.00x

EPS Incl Extra (TTM)$-1.58

ROI (TTM)-76.42%

P/S Ratio (TTM)15.66x

Pretax Margin (5Y Avg)-402.48%

Revenue / Share (Annual)$0.91

Tangible BV / Share (Annual)$4.71

Price vs S&P 500 (52W)97.78%

Year-to-Date Return66.38%

5-Day Price Return0.30%

EPS Normalized (Annual)$-2.03

ROA (5Y Avg)-38.91%

Net Profit Margin (Annual)-223.16%

Month-to-Date Return0.79%

Cash Flow / Share (TTM)$-3.11

EBITD / Share (Annual)$-2.06

Operating Margin (Annual)-228.28%

LT Debt / Equity (Annual)1.11x

ROI (5Y Avg)-43.24%

LT Debt / Equity (Quarterly)15.81x

EPS Basic Excl Extra (TTM)$-1.58

P/TBV (Quarterly)2.01x

P/B Ratio (Annual)7.18x

Pretax Margin (TTM)-94.06%

Book Value / Share (Annual)$1.92

Price vs S&P 500 (13W)60.75%

Beta-0.10x

P/FCF (Annual)156.69x

Revenue / Share (TTM)$1.67

ROE (TTM)-237.53%

52-Week Low$9.83

vGradeD

gGradeB

mGradeA

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.43est. -0.48

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.33

3.92

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
KALVKalVista Pharmaceuticals, Inc. Common Stock	D	B	A	$26.94
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

KalVista Pharmaceuticals develops oral small-molecule therapies targeting the kallikrein-kinin system for rare genetic and acquired disorders with significant unmet medical needs. The company's commercial product, EKTERLY (sebetralstat), is an FDA-approved plasma kallikrein inhibitor for acute hereditary angioedema (HAE) attacks in patients aged 12 and older. Leveraging its novel oral drug discovery platform, KalVista is positioned to address multiple orphan indications in disease areas with limited treatment options.